S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CMPS

COMPASS Pathways (CMPS) Stock Price, News & Analysis

$8.32
-1.18 (-12.42%)
(As of 03/28/2024 ET)
Today's Range
$8.12
$9.35
50-Day Range
$8.03
$12.37
52-Week Range
$5.01
$12.75
Volume
3.56 million shs
Average Volume
722,174 shs
Market Capitalization
$515.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.00

COMPASS Pathways MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
488.9% Upside
$49.00 Price Target
Short Interest
Healthy
5.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of COMPASS Pathways in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1.06 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.45) to ($2.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.90 out of 5 stars

Medical Sector

431st out of 862 stocks

Pharmaceutical Preparations Industry

198th out of 389 stocks

CMPS stock logo

About COMPASS Pathways Stock (NASDAQ:CMPS)

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

CMPS Stock Price History

CMPS Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Mental Health Mavericks: 3 Stocks Changing the Game
CMPS Mar 2024 10.000 call
COMPASS Pathways plc (CMPS)
See More Headlines
Receive CMPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CMPS
Fax
N/A
Employees
186
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$49.00
High Stock Price Target
$120.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+488.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-118,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.65 per share

Miscellaneous

Free Float
47,083,000
Market Cap
$515.34 million
Optionable
Optionable
Beta
2.52

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. George Jay Goldsmith (Age 69)
    Chairman & Co-founder
    Comp: $826.37k
  • Mr. Kabir Nath M.A. (Age 60)
    M.B.A., CEO & Director
    Comp: $952.19k
  • Dr. Ekaterina Malievskaia M.D. (Age 58)
    Co-Founder & Director
    Comp: $567.91k
  • Mr. Matthew Allen Owens (Age 47)
    General Counsel & Chief Legal Officer
    Comp: $659.53k
  • Ms. Teri Loxam M.B.A. (Age 51)
    CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. Greg Ryslik Ph.D.
    Chief Technology Officer
  • Mr. Stephen D. Schultz
    Senior Vice President of Investor Relations
  • Mr. Christopher Williams
    Chief Communications Officer
  • Ms. Anne Benedict
    Chief People Officer
  • Mr. Lars Christian Wilde (Age 39)
    Senior Advisor

CMPS Stock Analysis - Frequently Asked Questions

Should I buy or sell COMPASS Pathways stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMPS shares.
View CMPS analyst ratings
or view top-rated stocks.

What is COMPASS Pathways' stock price target for 2024?

5 equities research analysts have issued 12-month price targets for COMPASS Pathways' stock. Their CMPS share price targets range from $16.00 to $120.00. On average, they expect the company's stock price to reach $49.00 in the next year. This suggests a possible upside of 488.9% from the stock's current price.
View analysts price targets for CMPS
or view top-rated stocks among Wall Street analysts.

How have CMPS shares performed in 2024?

COMPASS Pathways' stock was trading at $8.75 at the start of the year. Since then, CMPS shares have decreased by 4.9% and is now trading at $8.32.
View the best growth stocks for 2024 here
.

Are investors shorting COMPASS Pathways?

COMPASS Pathways saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 3,150,000 shares, a decrease of 15.8% from the February 29th total of 3,740,000 shares. Based on an average trading volume of 680,400 shares, the short-interest ratio is currently 4.6 days.
View COMPASS Pathways' Short Interest
.

When is COMPASS Pathways' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CMPS earnings forecast
.

How were COMPASS Pathways' earnings last quarter?

COMPASS Pathways plc (NASDAQ:CMPS) posted its quarterly earnings results on Thursday, February, 29th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.16.

What ETFs hold COMPASS Pathways' stock?

ETFs with the largest weight of COMPASS Pathways (NASDAQ:CMPS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Subversive Mental Health ETF (SANE) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).ARK Genomic Revolution ETF (ARKG).

What other stocks do shareholders of COMPASS Pathways own?

Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Block (SQ), Workhorse Group (WKHS) and

When did COMPASS Pathways IPO?

COMPASS Pathways (CMPS) raised $100 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are COMPASS Pathways' major shareholders?

COMPASS Pathways' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (4.23%), Affinity Asset Advisors LLC (0.89%), Barclays PLC (0.81%), Sumitomo Mitsui Trust Holdings Inc. (0.59%), Nikko Asset Management Americas Inc. (0.59%) and PFM Health Sciences LP (0.55%). Insiders that own company stock include David Y Norton, Ekaterina Malievskaia and George Jay Goldsmith.
View institutional ownership trends
.

How do I buy shares of COMPASS Pathways?

Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMPS) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners